# HAS (France) Health Technology Assessment Report
## Luxturna (Voretigène Néparvovec) for Inherited Retinal Dystrophy

**Agency:** Haute Autorité de Santé (HAS)
**Country:** France
**Product Name:** LUXTURNA (voretigène néparvovec)
**Assessment Dates:**
- Initial Opinion: April 3, 2019
- Reassessment: July 19, 2023
- Latest Reassessment: July 17, 2024
**Report URL:** https://www.has-sante.fr/jcms/pprd_2982790/fr/luxturna-voretigene-neparvovec

---

## EXECUTIVE SUMMARY

The Haute Autorité de Santé (HAS) conducted health technology assessments of voretigene neparvovec (Luxturna) for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 gene mutations. HAS issued multiple favorable opinions for reimbursement in the French healthcare system, with periodic reassessments as required.

### Key Determination
HAS granted voretigene neparvovec an **"important" judgment (ASMR II rating)**, recognizing it as providing significant therapeutic improvement in an area of major unmet medical need.

---

## HAS ASSESSMENT FRAMEWORK

### French HTA System Overview

**Two Key Assessments by HAS:**

1. **SMR (Service Médical Rendu) - Actual Medical Benefit:**
   - Evaluates the overall therapeutic value of the drug
   - Considers disease severity, efficacy, safety, and place in therapeutic strategy
   - Determines whether drug should be reimbursed

2. **ASMR (Amélioration du Service Médical Rendu) - Improvement in Actual Medical Benefit:**
   - Assesses improvement over existing treatments
   - Rated on a scale from ASMR I (major) to ASMR V (no improvement)
   - Directly influences pricing and reimbursement level

---

## INDICATION

**Approved Therapeutic Indication:**
Treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

**Disease Context:**
- Inherited retinal dystrophies including:
  - Retinitis pigmentosa (retinopathie pigmentaire)
  - Leber congenital amaurosis (amaurose congénitale de Leber)
- Caused by biallelic mutations in the RPE65 gene
- Progressive vision loss leading to severe visual impairment and blindness

---

## HAS OPINION AND RECOMMENDATIONS

### Reimbursement Opinion: **FAVORABLE**

HAS issued favorable opinions for reimbursement of Luxturna in the French healthcare system across multiple assessment cycles:
- April 3, 2019 (Initial assessment)
- July 19, 2023 (Reassessment)
- July 17, 2024 (Latest reassessment)

### ASMR Rating: **ASMR II (Important Improvement)**

**Rating Definition:**
ASMR II represents an "important improvement in actual medical benefit" compared to existing therapeutic options.

**Justification for ASMR II:**
- First disease-modifying treatment for this orphan condition
- Significant improvement in patients' functional vision
- Addresses major unmet medical need
- One-time gene therapy intervention
- Prevention of progression to complete blindness

---

## CLINICAL ASSESSMENT

### Disease Severity Assessment

**HAS Evaluation of Disease Impact:**
- RPE65-mediated inherited retinal dystrophy is a **severe, progressive condition**
- Leads to profound visual impairment and blindness
- Major impact on quality of life and daily functioning
- Affects both children and adults
- Progressive deterioration with no previous disease-modifying treatments

### Clinical Efficacy Evidence

**Pivotal Studies Reviewed:**
- Study 301 (Phase 3 randomized controlled trial)
- Study 101 (Phase 1/2 long-term follow-up study)

**Primary Efficacy Outcomes:**
1. **Multi-Luminance Mobility Testing (MLMT):**
   - Significant improvement in mobility at various light levels
   - Clinically meaningful benefit in functional vision
   - Sustained improvements in long-term follow-up

2. **Visual Acuity:**
   - Variable improvements across patients
   - Some patients showed meaningful gains
   - Others maintained stable vision preventing further deterioration

3. **Visual Field:**
   - Improvements in visual field measurements
   - Prevention of progressive field loss
   - Inter-individual variability in response

**HAS Assessment of Evidence:**
- Clinical benefit demonstrated across multiple vision-related outcomes
- Significant improvement in patients' functional vision capabilities
- Evidence of sustained benefit in available follow-up period
- First treatment showing disease-modifying effects

### Limitations and Uncertainties Acknowledged

**Evidence Gaps Identified:**
1. **Absence of long-term data:**
   - Limited follow-up beyond 3-4 years at time of assessment
   - Uncertainty about lifetime durability of treatment effect
   - Need for continued post-market surveillance

2. **Absence of quality of life data:**
   - Limited patient-reported outcome measures
   - Lack of validated QoL instruments for this specific population
   - Need for comprehensive quality of life assessment

3. **Limited comparative data:**
   - Comparison to natural history and best supportive care
   - No active treatment comparators (as none exist)
   - Challenges in quantifying precise magnitude of benefit

---

## SAFETY ASSESSMENT

### Safety Profile Evaluation

**HAS Review of Safety Data:**
- Generally acceptable safety profile
- Adverse events primarily related to surgical procedure
- Manageable complications

**Main Safety Findings:**

**Ocular Adverse Events:**
- Conjunctival hyperemia (redness)
- Cataract formation
- Increased intraocular pressure
- Retinal abnormalities
- Eye inflammation
- Most events manageable with standard ophthalmologic interventions

**Systemic Adverse Events:**
- Limited systemic safety concerns
- No major immunologic reactions to gene therapy vector
- Safety profile consistent with subretinal injection procedure

**Long-term Safety:**
- HAS noted the need for continued long-term safety monitoring
- Post-authorization safety studies required
- Registry participation for real-world safety data

---

## PLACE IN THERAPEUTIC STRATEGY

### Current Treatment Landscape

**Before Luxturna:**
- No disease-modifying treatments available
- Management limited to:
  - Low vision aids and assistive devices
  - Orientation and mobility training
  - Vision rehabilitation services
  - Supportive care
  - Genetic counseling

**With Luxturna:**
- First disease-modifying gene therapy
- Potential to prevent progression to blindness
- One-time intervention
- Requires specialized treatment centers

### HAS Positioning
Luxturna represents a **therapeutic breakthrough** in the management of RPE65-mediated inherited retinal dystrophy, providing the first opportunity to modify disease progression in this orphan condition.

---

## TARGET POPULATION

### Eligible Patients in France

**Inclusion Criteria:**
- Confirmed biallelic RPE65 gene mutations (genetic testing required)
- Vision loss due to inherited retinal dystrophy
- Sufficient viable retinal cells remaining
- Both pediatric and adult patients eligible

**Estimated Population:**
- Ultra-rare condition
- Estimated eligible population in France: limited number of patients
- Both prevalent cases (existing patients) and incident cases (new diagnoses)

**Patient Selection Process:**
- Genetic confirmation essential
- Ophthalmologic assessment of retinal viability
- Evaluation by specialized inherited retinal disease centers
- Multidisciplinary team assessment

---

## THERAPEUTIC INNOVATION ASPECTS

### HAS Recognition of Innovation

**Gene Therapy Innovation:**
- First gene therapy approved for inherited retinal disease in France
- One-time administration paradigm
- Subretinal delivery of functional RPE65 gene
- Proof of concept for gene therapy in ophthalmology

**Clinical Innovation:**
- First disease-modifying treatment for this condition
- Addresses previously untreatable genetic disease
- Potential for long-term sustained benefit from single intervention

**Broader Implications:**
- Paves way for other gene therapies for retinal diseases
- Demonstrates feasibility of genetic correction for inherited eye diseases
- Innovation in rare disease treatment development

---

## ECONOMIC CONSIDERATIONS

### Cost and Budget Impact

**Drug Cost:**
- High unit cost: €613,410 per patient (both eyes)
- One-time treatment cost
- Includes drug product for bilateral subretinal injection

**Additional Healthcare Costs:**
- Pre-treatment assessment:
  - Genetic testing
  - Comprehensive ophthalmologic evaluation
  - Retinal imaging
- Surgical procedure:
  - Specialized surgical team
  - Operating room costs
  - Anesthesia
  - Hospital stay
- Post-treatment monitoring:
  - Regular follow-up visits
  - Long-term ophthalmologic monitoring
  - Management of complications if needed

**Budget Impact Assessment:**
- Limited number of eligible patients (orphan condition)
- One-time treatment per patient
- Front-loaded costs vs. lifetime benefits
- Potential offset by reduced supportive care costs over time

### Pricing and Reimbursement Negotiation

Following HAS favorable opinion with ASMR II rating:
- Price negotiated between manufacturer (Novartis) and CEPS (Comité Économique des Produits de Santé)
- ASMR II rating supports higher negotiated price
- Reimbursement rate determined by Social Security
- Inclusion on list of reimbursable medications

---

## TREATMENT DELIVERY REQUIREMENTS

### Specialized Centers

**Infrastructure Requirements:**
- Tertiary ophthalmology centers with:
  - Expertise in inherited retinal diseases
  - Experienced vitreoretinal surgeons
  - Genetic testing and counseling services
  - Appropriate surgical facilities
  - Pediatric ophthalmology expertise

**Geographic Distribution in France:**
- Limited number of reference centers (centres de référence)
- Typically located in university hospitals (CHU)
- Coordination with competence centers nationwide
- Need for patient travel to specialized centers in some cases

### Multidisciplinary Team

**Required Expertise:**
- Medical geneticists
- Ophthalmologists specializing in inherited retinal diseases
- Vitreoretinal surgeons
- Genetic counselors
- Low vision specialists
- Pediatric specialists (for childhood cases)

---

## POST-MARKET SURVEILLANCE AND REAL-WORLD EVIDENCE

### HAS Requirements for Ongoing Monitoring

**Post-Authorization Studies:**
- Long-term effectiveness monitoring
- Real-world safety surveillance
- Durability of treatment effect assessment
- Quality of life impact measurement

**Registry Participation:**
- European and national registries for gene therapy
- Rare disease registries
- Long-term outcome tracking

**Periodic Reassessment:**
- HAS conducts periodic reassessments (as evidenced by 2023 and 2024 reviews)
- Review of new evidence as it becomes available
- Potential modification of recommendations based on real-world data
- Continued evaluation of benefit-risk balance

---

## PATIENT AND STAKEHOLDER INPUT

### Patient Perspectives

**Impact on Quality of Life:**
- Severe burden of progressive vision loss
- Loss of independence and ability to perform daily activities
- Impact on education and employment
- Psychological impact of anticipated blindness
- Caregiver burden on families

**Patient Expectations:**
- Strong desire for disease-modifying treatment
- Hope for preservation of remaining vision
- Willingness to accept one-time intervention
- Recognition of need for specialized care delivery

### Healthcare Professional Input

**Clinical Expert Opinions:**
- Major unmet need in this patient population
- Importance of early diagnosis and genetic testing
- Need for specialized centers and surgical expertise
- Importance of appropriate patient selection
- Requirement for long-term follow-up

---

## COMPARATIVE INTERNATIONAL CONTEXT

### HAS Assessment in European Context

**Alignment with EMA:**
- HAS assessment follows EMA marketing authorization
- Indication aligned with European approval
- Safety and efficacy data from EMA submission

**Comparison with Other European Countries:**
- Similar positive recommendations in other EU countries
- Recognition of orphan status and unmet need
- Variation in reimbursement and pricing across countries
- Shared challenges regarding long-term evidence and high costs

---

## KEY STRENGTHS OF EVIDENCE

### HAS-Identified Strengths

1. **Randomized Controlled Trial:**
   - Study 301 provided comparative evidence vs. control
   - Multiple objective outcome measures
   - Consistent direction of benefit

2. **Long-term Follow-up:**
   - Study 101 provided data beyond primary endpoint
   - Evidence of sustained benefit
   - Safety profile over extended period

3. **Multiple Outcome Measures:**
   - Functional mobility testing (MLMT)
   - Visual acuity
   - Visual field
   - Light sensitivity testing

4. **Biological Plausibility:**
   - Clear genetic target (RPE65 mutations)
   - Mechanism of action well-understood
   - Proof of genetic correction and protein expression

5. **Unmet Medical Need:**
   - No previous disease-modifying treatments
   - Severe, progressive, blinding condition
   - Orphan disease with small patient population

---

## KEY LIMITATIONS AND UNCERTAINTIES

### HAS-Identified Limitations

1. **Limited Long-term Data:**
   - Follow-up limited to 3-4 years at initial assessment
   - Uncertainty about lifetime durability
   - Need for extended real-world follow-up

2. **Quality of Life Data Gaps:**
   - Limited patient-reported outcomes
   - Lack of validated disease-specific QoL instruments
   - Uncertainty about full impact on daily functioning

3. **Small Sample Sizes:**
   - Limited by disease rarity
   - Challenges in statistical power
   - Variability in individual responses

4. **Outcome Measure Challenges:**
   - Inter-test variability in some measures
   - Lack of fully validated endpoints
   - Challenges in clinical meaningfulness interpretation

5. **Optimal Treatment Timing:**
   - Uncertainty about best age or disease stage for intervention
   - Balance between early intervention and ensuring diagnosis accuracy

---

## HAS MONITORING AND REEVALUATION

### Periodic Reassessment Process

**2019 Initial Assessment:**
- Favorable opinion for reimbursement
- ASMR II rating granted
- Based on pivotal trial data and early follow-up

**2023 Reassessment:**
- Review of accumulated post-market data
- Updated safety information
- Extended efficacy follow-up
- Continued favorable opinion

**2024 Latest Reassessment:**
- Most recent review of evidence
- Real-world effectiveness data
- Long-term safety profile
- Maintained favorable reimbursement opinion

### Ongoing Evidence Requirements

**HAS Expectations:**
- Continued participation in registries
- Long-term outcome reporting
- Real-world effectiveness studies
- Quality of life assessments
- Pharmacovigilance activities

---

## IMPLEMENTATION IN FRENCH HEALTHCARE SYSTEM

### Access Pathway for Patients

1. **Diagnosis and Genetic Confirmation:**
   - Referral to inherited retinal disease specialist
   - Comprehensive ophthalmologic evaluation
   - Genetic testing for RPE65 mutations
   - Assessment of retinal viability

2. **Eligibility Evaluation:**
   - Multidisciplinary team assessment
   - Confirmation of criteria
   - Discussion of risks and benefits
   - Informed consent process

3. **Treatment Planning:**
   - Coordination with specialized surgical center
   - Pre-operative assessment
   - Scheduling of bilateral procedures
   - Patient and family education

4. **Post-Treatment Follow-up:**
   - Regular ophthalmologic monitoring
   - Assessment of treatment response
   - Long-term outcome tracking
   - Management of complications if needed

### Reimbursement Process

- Listed on French reimbursable medications list
- Reimbursed by Social Security (Assurance Maladie)
- Typically 100% coverage for chronic severe diseases (ALD)
- Hospital-based administration with associated procedure costs covered

---

## BROADER VALUE CONSIDERATIONS

### Societal Benefits

**Beyond Direct Health Benefits:**
- Prevention of blindness and associated disability
- Potential for maintained employment and education
- Preservation of independence and quality of life
- Reduced caregiver burden
- Broader benefits to families and society

**Economic Considerations:**
- One-time cost vs. lifetime benefit
- Potential offset of long-term disability costs
- Impact on productivity and social participation
- Innovation value for future gene therapies

---

## CONCLUSIONS

### HAS Overall Assessment

Voretigene neparvovec (Luxturna) represents an **important therapeutic advance (ASMR II)** for patients with RPE65-mediated inherited retinal dystrophy. HAS determined that:

✓ **Favorable opinion for reimbursement** is warranted
✓ **Significant improvement in functional vision** demonstrated
✓ **First and only disease-modifying treatment** for this orphan condition
✓ **Acceptable benefit-risk balance** in this severe disease
✓ **Important unmet medical need** addressed

### Conditions and Monitoring

Reimbursement is subject to:
- Appropriate patient selection by specialized centers
- Genetic confirmation of biallelic RPE65 mutations
- Adequate viable retinal tissue
- Expert administration by qualified surgeons
- Continued post-market surveillance
- Periodic reassessment by HAS

---

## REFERENCES

1. Haute Autorité de Santé. LUXTURNA (voretigène néparvovec) - Avis sur les Médicaments. Available at: https://www.has-sante.fr/jcms/pprd_2982790/fr/luxturna-voretigene-neparvovec

2. Haute Autorité de Santé. LUXTURNA (voretigene neparvovec) - Dystrophie rétinienne héréditaire. Assessment dated July 17, 2024. Available at: https://www.has-sante.fr/jcms/p_3538246

3. Haute Autorité de Santé. LUXTURNA (voretigène néparvovec) - Initial assessment dated April 3, 2019. Available at: https://www.has-sante.fr/jcms/c_2964759/fr/luxturna-voretigene-neparvovec

4. Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies. PMC9483157.

---

## DOCUMENT INFORMATION

**Compiled from:** HAS official opinions and assessments, published literature on French HTA processes, and comparative analyses
**Report Compilation Date:** November 11, 2025
**Status:** Favorable opinion maintained through 2024 reassessment
**Language Note:** Original HAS documents in French; key information translated and summarized in English
**Assessment History:** Initial 2019, Reassessed 2023, Latest assessment 2024
